Effects of the dipeptide L-glutamic acid-L-tryptophan on dermatitis in mice and human keratinocytes

Heliyon

卷:8

Masayo Sakaki-Yumoto¹  Akiko Kuwahara²  Makoto Kawaguchi³  Tsuyoshi Ishii³  Yoichi Honma³  Shun Shibata³ 

[1] Corresponding author.;

[2] Department of Informative Genetics, Tohoku University Graduate School of Medicine, 980-8575, Sendai, Japan;

[3] Basic Research Development Division, ROHTO Pharmaceutical Co., Ltd., Osaka 544-8666, Japan;

关键词: Allergic contact dermatitis;    Atopic dermatitis;    Interleukin-22;    Dipeptide;    L-Glu-L-Trp;   

DOI  :  

来源: DOAJ

【 摘 要 】

Allergic contact dermatitis (ACD) and atopic dermatitis (AD) are inflammatory eczematous skin diseases caused by various factors. Here, we report that topical application of the dipeptide, L-glutamic acid-L-tryptophan (L-Glu-L-Trp), improved symptoms in both ACD and AD in mice. Using a mouse model of ACD induced by repeated application of 2,4-dinitorofluorbenzene (DNFB), we demonstrated that L-Glu-L-Trp attenuated DNFB-induced skin thickening. In addition, quantification of cytokines in serum revealed that L-Glu-L-Trp suppressed the DNFB-induced increase in the interleukin (IL)-22 level. Moreover, L-Glu-L-Trp attenuated mite antigen extract-induced AD model symptoms such as the increase of skin thickening and elevation of serum IL-22. We also confirmed that the dipeptide structure rather than the individual amino acid components was important for the therapeutic effects of L-Glu-L-Trp. Furthermore, we showed that IL-22 decreased the expression level of filaggrin mRNA in human epidermal keratinocytes, and L-Glu-L-Trp attenuated that effect. These results suggested that the topical application of the dipeptide, L-Glu-L-Trp, to the skin may be useful for treating ACD and AD.

【 授权许可】

Unknown